RoosterBio Archives | BioInformant

Best Practices in MSC Culture: Tracking and Reporting Cellular Age Using Population Doubling Level (PDL)

November 17, 2024 By BioInformant Team Leave a Comment

Author: Jon Rowley, RoosterBio

This is a guest post from RoosterBio. RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.

There has been much discussion in the literature and the blogosphere (here, here, and here) lately about keeping track of cellular age, and there is very good reason for this. First, there are multiple regulatory guidelines that propose tracking the age of cells used in biologics manufacturing. Secondly, it is well documented that cell phenotype and function can be compromised the older a cell is. A few examples from the literature as this relates to human Mesenchymal Stem Cells (hMSCs) are: [Read more…]

How 3D Printing with Stem Cells will Alter the Future of Medicine

November 3, 2023 By Cade Hildreth, Founder & President Leave a Comment

Without question, 3D printing is one of the most transformative technologies of the 21st century, impacting diverse fields that include medicine, science, technology, manufacturing, military defense, and more. Among its exciting and varied applications, combining 3D printing technologies with stem cells is one of the most exciting.

For this reason, this article explores critical advances in 3D printing and how this technology is creating positive opportunities for stem cell companies and investors.

[Read more…]

First Patient Dosed in Phase I Clinical Trial using RoosterBio’s Cellular Starting Materials

March 4, 2020 By Cade Hildreth, Founder & President Leave a Comment

Investigational New Drug (IND) Using RoosterBio’s CliniControl™ Products Enters the Clinic by RoosterBio’s Pharmaceutical Customer

RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announces today a significant milestone in the regenerative medicine field with the dosing of the first patient using its innovative cellular starting materials. The patient has been treated by RoosterBio’s pharmaceutical customer with an Investigational New Drug (IND) that was manufactured using RoosterBio’s CliniControl cell and media systems. [Read more…]

RoosterBio Launches the Only Umbilical Cord hMSC System in the World Designed for Perinatal Cell Therapy Product Development

September 24, 2019 By Cade Hildreth, Founder & President 2 Comments

RoosterBio, Inc, a biotechnology market disrupter and leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, released the Regenerative Medicine industry’s first human umbilical cord (hUC) MSC paired cell and media system designed for product development and bringing with it an unprecedented step-change in quantifiable productivity metrics. RoosterVial™-hUC-MSC-XF, allows scientists to generate billions of perinatal cells in a fraction of the time when paired with RoosterBio’s existing xeno-free (XF) hMSC plug and play systems. This product line is the only commercially available, high-volume perinatal MSC bioprocess system with a line of sight to towards clinical translation. [Read more…]

Introducing the Dawn of MSCs with RoosterBio Founder, Jon Rowley

August 6, 2019 By Cade Hildreth, Founder & President Leave a Comment

Founded by Dr. Jon Rowley, RoosterBio is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry. Its products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. I had the honor of interviewing Dr. Jon Rowley, who is now the CTO of RoosterBio.

In this interview, we explore RoosterBio’s recent product launches, collaborations, achievements and future trajectory. [Read more…]